GO Therapeutics Enters into a License Agreement with Roche for New Glycotargeting Bispecific Cancer Treatment

On October 2, 2018 GO Therapeutics, Inc. (GO), a company applying new advances in glycoproteomics to develop antibody-based cancer therapeutics, reported that it has entered into a license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche) (Press release, GO Therapeutics, OCT 2, 2018, View Source [SID1234529713]). Under the terms of the agreement, GO will grant Roche a worldwide, exclusive license for antibodies generated to address a novel cancer-specific target to develop and commercialize a new glycotargeting bispecific antibody.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited about this collaboration to develop an innovative immune-redirected therapy to potentially improve the lives of patients suffering from cancer in the future"

Under the terms of the agreement, Roche will pay GO upfront and near-term milestones of $9 million. GO will also be eligible to receive up to $186 million in potential milestone payments as well as mid-single-digit to low double-digit royalties on any future product sales. Further details about the transaction were not disclosed.

"We are excited about this collaboration to develop an innovative immune-redirected therapy to potentially improve the lives of patients suffering from cancer in the future," said Constantine Theodoropulos, chief executive officer of GO Therapeutics.

"GO’s glycoprotein targeting platform opens an exciting class of tumor-specific antigens that can help widen the therapeutic window for cancer therapies such as T-cell bispecific antibodies, CAR-T and ADCs (Antibody Drug Conjugates). Preclinical data show GO’s approach can provide superior specificity in targeting solid tumors over normal tissue, and demonstrate clean in-vivo toxicity profiles in the context of potent immunotherapies."